Quantum Genomics and Biolab Sanus Pharmaceutical have signed an exclusive agreement for firibastat in Latin America

Quantum Genomics has granted an exclusive license to Biolab Sanus Pharmaceutical to develop and commercialize firibastat for the treatment of hypertension in Latin America.

Quantum Genomics (Euronext Growth – FR0011648971 – ALQGC), a biopharmaceutical company specializing in the development of a new class of drugs directly acting on the brain to treat high blood pressure and heart failure, and Biolab Sanus Pharmaceutical, one of five largest pharmaceutical companies in Brazil, announce the signature of an exclusive license and collaboration agreement to develop and commercialize firibastat in Latin America. This is the first regional partnership for Quantum Genomics.

Read the press release

Leave a Reply

Your email address will not be published.